Evidence map›Paper›PMID 32060777›Full record

ArticleEJNMMI physics2020

Comprehensive SPECT/CT system characterization and calibration for

Andrea Frezza, Corentin Desport, Carlos Uribe, Wei Zhao, Anna Celler, Philippe Després, Jean-Mathieu Beauregard

Open access · goldAbstract read
In one paragraph

Article in EJNMMI physics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Count-rate management inEJNMMI physics · 2025
    Article
  7. Article
  8. Validation ofEJNMMI physics · 2023
    Article
  9. Article
  10. Article
  11. Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Recommendations for Multicentre Clinical Trials Involving Dosimetry for Molecular Radiotherapy.Clinical oncology (Royal College of Radiologists (Great Britain)) · 2021
    Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Andrea FrezzaCancer Research Center, Université Laval, Quebec City, QC, Canada.
Corentin DesportCancer Research Center, Université Laval, Quebec City, QC, Canada.
Carlos UribeFunctional Imaging Department, BC Cancer, Vancouver, BC, Canada.
Wei ZhaoMedical Imaging Research Group, Department of Radiology, University of British Columbia, Vancouver, BC, Canada.
Anna CellerMedical Imaging Research Group, Department of Radiology, University of British Columbia, Vancouver, BC, Canada.
Philippe DesprésCancer Research Center, Université Laval, Quebec City, QC, Canada.
Jean-Mathieu BeauregardCancer Research Center, Université Laval, Quebec City, QC, Canada. jean-mathieu.beauregard@chudequebec.ca.ORCID http://orcid.org/0000-0003-2123-145X
Université Laval · CAUniversity of British Columbia · CAHôtel-Dieu de Québec · CA

Funding

CIHR MOP-142233Fonds de Recherche du Québec - Santé n/a
6 · The paper itself

Abstract

backgroundPersonalization of

methodsThe SPECT/CT camera was equipped with a medium energy collimator. Multiple phantoms were used to reproduce various attenuation conditions: rod sources in air or water-equivalent media, as well as a Jaszczak phantom with inserts. Planar and tomographic images of a wide range of activities were acquired, with multiple energy windows for scatter correction (double or triple energy window technique) as well as count rate monitoring over a large spectrum of energy. Dead time was modelled using the paralysable model. CF and τ were deduced by curve fitting either separately in two steps (CF determined first using a subset of low-activity acquisitions, then τ determined using the full range of activity) or at once (both CF and τ determined using the full range of activity). Total or segmented activity in the SPECT field of view was computed. Finally, these methods were compared in terms of accuracy to recover the known activity, in particular when planar-derived parameters were applied to the SPECT data.

resultsThe SPECT camera was shown to operate as expected on a finite count rate range (up to ~ 350 kcps over the entire energy spectrum). CF and τ from planar (sources in air) and SPECT segmented Jaszczak data yielded a very good agreement (CF < 1% and τ < 3%). Determining CF and τ from a single curve fit made dead-time-corrected images less prone to overestimating recovered activity. Using triple-energy window scatter correction while acquiring one or more additional energy window(s) to enable wide-spectrum count rate monitoring (i.e. ranging 55-250 or 18-680 keV) yielded the most consistent results across the various geometries. The final, planar-derived calibration parameters for our system were a CF of 9.36 ± 0.01 cps/MBq and a τ of 0.550 ± 0.003 μs. Using the latter, the activity in a Jaszczak phantom could be quantified by QSPECT with an accuracy of 0.02 ± 1.10%.

conclusionsSerial planar acquisitions of sources in air using an activity range covering the full operational capacity of the SPECT/CT system, with multiple energy windows for wide-spectrum count rate monitoring, and followed by simultaneous determination of CF and τ using a single equation derived from the paralysable model, constitutes a practical method to enable accurate dead-time-corrected QSPECT imaging in a post-

Indexed as

177LuCalibrationDead timeQuantitative SPECTSPECT/CT

Identifiers

PMID32060777
PMCPMC7021856
OpenAlexW3012747988

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.